US Starts Clinical Trial for mRNA Nipah Virus Vaccine
The experimental Nipah virus vaccine (mRNA-1215) is manufactured by Moderna, Inc. and was developed in collaboration with NIAID’s Vaccine Research ...
Tag: NIAID
US Begins Phase 1 Clinical Trial of Universal Flu Vaccine
A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the National Institutes ...
NIAID Funding Available for Biocontainment Facility Improvements
NIAID supports Biodefense and Emerging Infectious Diseases Research Infrastructure as a key component of our mission to safely and effectively ...
NIH Awards $3M Grant to Albany Med for Plague Vaccine Development
Albany Medical College scientists have been awarded a $3 million, five-year federal grant to develop a vaccine that could protect ...
Bacterial and Viral Bioinformatics Resource Center Website Now Available
The Bacterial and Viral Bioinformatics Resource Center (BV-BRC), an initiative funded by the National Institute of Allergy and Infectious Diseases (NIAID), ...
Bucknell Researchers Head to Uganda to Study African Bats’ Immune Response to Ebola Virus
In 2021, Bucknell University biology professors DeeAnn Reeder and Ken Field received a $2.9 million grant from the National Institute ...
How Well Do Covid Vaccines Hold Up Over Time? Macaque Study Shows Decline in Lung Protection
The findings point to the need for mRNA-1273 booster vaccination to sustain high-level and rapid protection in the lung and ...
UTHSC Awarded $3.2 Million for Upgrades to Regional Biocontainment Laboratory
The University of Tennessee Health Science Center has been awarded $3.2 million from the National Institute of Allergy and Infectious ...
U.S. Invests $36.3M in Pan-Coronavirus Vaccine Development
The awards are intended to fuel vaccine research for a diverse family of coronaviruses, with a primary focus on potential ...
Licensing Opportunity: Virus-Like Particle Technology for Universal Flu Vaccine
Reformulating influenza vaccines annually against dominant circulating strains leads to variable protective efficacy and is unlikely to protect against novel ...
RFI Supports Research on Impact of Nuclear Incident on the Microbiome and Development of Targeted Therapeutics
The National Institute of Allergy and Infectious Diseases (NIAID) is soliciting input from the radiation biology and microbiome research communities ...
Nanoparticle Mosaic Quadrivalent Flu Vaccine Phase 1 Clinical Trial Gets Underway
NIH Launches Clinical Trial of Universal Influenza Vaccine Candidate A first-in-human, Phase 1 trial assessing the safety and immunogenicity of ...
2021 BAA for Development of Medical Countermeasures for Biological Threats
The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), is soliciting research ...
Human Spillover Potential of Reston Ebolavirus Noted by NIAID Study
New research shows pigs could serve as amplifying hosts for Reston ebolavirus. Reston ebolavirus (RESTV) should be considered a livestock ...
Neutralizing Norovirus: NIAID Monoclonal Antibodies Licensing Opportunity
The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in ...
NIAID Looks Ahead to Pan-Coronavirus Vaccine Candidates
With multiple promising SARS-CoV-2 vaccine candidates now under development, the National Institute of Allergy and Infectious Diseases (NIAID) is looking ...
Scent of a Virus: NIH Seeks Novel Tech to Detect COVID-19 From Skin Odors
The National Institutes of Health is fast-tracking funding for development of novel, non-traditional approaches to identify the current SARS-CoV-2 virus ...
NIAID Establishes New Global Network to Focus on Spillover Potential of Emerging Diseases
The new Centers for Research in Emerging Infectious Diseases (CREID) — comprised of 10 research centers and a coordinating center — is ...
Moderna’s COVID-19 Vaccine Generally Well Tolerated in Ongoing Phase 1 Trial
An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well ...
NIAID to Hold Closed Meeting on Biodefense Medical Countermeasure Funding
A Special Emphasis Panel of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of ...
